Welcome to our dedicated page for Health Catalyst SEC filings (Ticker: HCAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Health Catalyst, Inc. filings document operating results, material-event reporting, and governance changes for a Nasdaq-listed healthcare data and analytics company. Recent Form 8-K disclosures include quarterly and annual financial results, preliminary unaudited financial updates, and press-release exhibits furnished under results-of-operations items.
The company’s filings also cover board appointments, executive transitions, compensatory arrangements, transition and separation agreements, executive severance-plan references, workforce-reduction disclosures, and related governance matters. These records provide formal disclosure around Health Catalyst’s management structure, financial condition, and material corporate events.
Form 3 overview – Health Catalyst, Inc. (HCAT): On 06/25/2025, Chief Technology & Product Officer David Coy Ross filed an initial statement of beneficial ownership. The filing discloses direct ownership of 207,579 common shares, consisting of previously issued stock plus multiple tranches of restricted stock units (RSUs) granted under the 2019 Stock Option and Incentive Plan. The RSUs follow customary quarterly-vesting schedules, with the largest award (90,000 RSUs) beginning to vest on 12/01/2025 (33.33%) and the balance in eight equal quarterly installments. No derivative securities, purchases, or sales were reported; the Form 3 simply records the officer’s existing equity position as required under Section 16(a). The disclosure signals equity alignment between the newly reported executive and shareholders but does not by itself imply any immediate financial impact on HCAT.